Topical peptide spray outperforms placebo in healing burn wounds
News-Medical reports on a phase IIIb trial across 23 centers in China that randomized 348 adults with mild infected burn wounds to PL-5 (peceleganan) antimicrobial peptide spray or placebo once daily for 14 days. On day 15, complete healing was 64.3% versus 43.1%. Blood levels stayed below quantification limits. Follow-up was short, and PL-5 remains investigational.
Why it matters: Relevant to clinicians who treat mild infected burn wounds and to adults with such wounds who follow topical, antibiotic-sparing options still under investigation.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to news-medical.net. October 13, 2026.
